两种在胃肠道中具有不同组织学定位的选择性剪接小鼠尿激酶受体mRNA。
Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract.
作者信息
Kristensen P, Eriksen J, Blasi F, Danø K
机构信息
Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.
出版信息
J Cell Biol. 1991 Dec;115(6):1763-71. doi: 10.1083/jcb.115.6.1763.
Abstract
Two mouse urokinase-type plasminogen activator receptor (muPAR) cDNAs were isolated: muPAR1 is homologous to the human urokinase-type plasminogen activator receptor while muPAR2 codes for a 199 residue protein sharing the first 133 residues with muPAR1. Mouse genomic DNA sequencing indicates that the two different mRNAs arise by alternative splicing. In situ hybridization showed differential expression of the two mRNAs in mouse gastric mucosa. muPAR1 mRNA is located in luminal epithelial cells situated close to urokinase-type plasminogen activator-producing connective tissue cells of the lamina propria, pointing to plasmin generation controlled by the cooperation of different cells that may play a role in the release of gastric epithelial cells. muPAR2 mRNA is expressed in the basal epithelial cells, and the deduced protein sequence includes the receptor ligand binding domain, but omits the region involved in glycolipid-mediated membrane anchoring, suggesting that muPAR2 may code for a secreted uPA binding protein.
摘要
分离出了两种小鼠尿激酶型纤溶酶原激活物受体（muPAR）cDNA：muPAR1与人尿激酶型纤溶酶原激活物受体同源，而muPAR2编码一种由199个残基组成的蛋白质，与muPAR1共享前133个残基。小鼠基因组DNA测序表明，这两种不同的mRNA是通过可变剪接产生的。原位杂交显示这两种mRNA在小鼠胃黏膜中表达存在差异。muPAR1 mRNA位于靠近固有层产生尿激酶型纤溶酶原激活物的结缔组织细胞的腔面上皮细胞中，表明纤溶酶的产生受不同细胞合作的控制，这些细胞可能在胃上皮细胞的释放中起作用。muPAR2 mRNA在基底上皮细胞中表达，推导的蛋白质序列包括受体配体结合域，但省略了糖脂介导的膜锚定相关区域，提示muPAR2可能编码一种分泌型uPA结合蛋白。
相似文献
1
Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract.两种在胃肠道中具有不同组织学定位的选择性剪接小鼠尿激酶受体mRNA。
J Cell Biol. 1991 Dec;115(6):1763-71. doi: 10.1083/jcb.115.6.1763.
2
An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator.人尿激酶型纤溶酶原激活剂受体的一种可变剪接mRNA变体。
FEBS Lett. 1993 Jul 12;326(1-3):69-74. doi: 10.1016/0014-5793(93)81763-p.
3
Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.早期胎盘形成过程中恒河猴妊娠子宫中尿激酶、纤溶酶原激活物抑制剂及尿激酶受体的表达
Placenta. 2000 Mar-Apr;21(2-3):184-93. doi: 10.1053/plac.1999.0446.
4
Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts.
FEBS Lett. 1994 Jan 24;338(1):69-74. doi: 10.1016/0014-5793(94)80118-5.
5
Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.月经周期中子宫内膜组织中尿激酶型纤溶酶原激活剂（uPA）、其受体（uPAR）及其抑制剂（PAI-1）mRNA和蛋白的差异定位与表达。
Mol Hum Reprod. 2004 Sep;10(9):655-63. doi: 10.1093/molehr/gah081. Epub 2004 Jul 8.
6
Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.通过对尿激酶型纤溶酶原激活剂受体进行光亲和标记来鉴定参与配体结合的特定位点。位于uPAR结构域I和III中同等位置的残基参与复合配体结合位点的组装。
Biochemistry. 1998 Nov 24;37(47):16494-505. doi: 10.1021/bi981203r.
7
Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin.皮肤鳞状细胞癌中尿激酶型纤溶酶原激活物受体mRNA的癌细胞表达
J Invest Dermatol. 2001 Mar;116(3):353-8. doi: 10.1046/j.1523-1747.2001.01241.x.
8
Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.尿激酶型纤溶酶原激活剂及其受体和抑制剂在胃腺癌组织中的表达
J Korean Med Sci. 1996 Feb;11(1):33-7. doi: 10.3346/jkms.1996.11.1.33.
9
UVB increases urokinase-type plasminogen activator receptor (uPAR) expression.
J Invest Dermatol. 1999 Jul;113(1):69-76. doi: 10.1046/j.1523-1747.1999.00631.x.
10
Cloning, nucleotide sequencing and expression of cDNAs encoding mouse urokinase-type plasminogen activator.编码小鼠尿激酶型纤溶酶原激活剂的cDNA的克隆、核苷酸测序及表达
Eur J Biochem. 1985 Apr 15;148(2):225-32. doi: 10.1111/j.1432-1033.1985.tb08829.x.
引用本文的文献
1
suPAR: An Inflammatory Mediator for Kidneys.可溶性尿激酶型纤溶酶原激活物受体：肾脏的一种炎症介质。
Kidney Dis (Basel). 2022 Jun 8;8(4):265-274. doi: 10.1159/000524965. eCollection 2022 Jul.
2
suPAR, a Circulating Kidney Disease Factor.可溶性尿激酶型纤溶酶原激活物受体，一种循环性肾脏疾病因子。
Front Med (Lausanne). 2021 Oct 6;8:745838. doi: 10.3389/fmed.2021.745838. eCollection 2021.
3
uPAR isoform 2 forms a dimer and induces severe kidney disease in mice.uPAR 同种型 2 形成二聚体并在小鼠中诱导严重肾脏疾病。
J Clin Invest. 2019 Apr 2;129(5):1946-1959. doi: 10.1172/JCI124793.
4
Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.转基因乳腺癌的自发性肺和淋巴结转移与尿激酶受体uPAR无关。
Clin Exp Metastasis. 2015 Aug;32(6):543-54. doi: 10.1007/s10585-015-9726-1. Epub 2015 Jun 4.
5
A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.肾小球疾病中可溶性尿激酶型纤溶酶原激活物受体的重新评估
Kidney Int. 2015 Mar;87(3):564-74. doi: 10.1038/ki.2014.346. Epub 2014 Oct 29.
6
Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.单独给予重组可溶性尿激酶受体不足以在小鼠中诱导足细胞改变和蛋白尿。
J Am Soc Nephrol. 2014 Aug;25(8):1662-8. doi: 10.1681/ASN.2013040425. Epub 2014 May 1.
7
Serum suPAR in patients with FSGS: trash or treasure?FSGS 患者的血清 suPAR：垃圾还是珍宝？
Pediatr Nephrol. 2013 Jul;28(7):1041-8. doi: 10.1007/s00467-013-2452-5. Epub 2013 Mar 21.
8
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.循环尿激酶受体是局灶节段性肾小球硬化的病因。
Nat Med. 2011 Jul 31;17(8):952-60. doi: 10.1038/nm.2411.
9
Membrane-anchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/progenitor cells.膜锚定的尿激酶型纤溶酶原激活物受体调节小鼠造血干细胞/祖细胞的增殖、骨髓池大小、植入和动员。
J Clin Invest. 2009 Apr;119(4):1008-18. doi: 10.1172/JCI36010. Epub 2009 Mar 9.
10
Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.与拮抗剂肽结合的人尿激酶型纤溶酶原激活物受体的晶体结构
EMBO J. 2005 May 4;24(9):1655-63. doi: 10.1038/sj.emboj.7600635. Epub 2005 Apr 7.
本文引用的文献
1
A comprehensive set of sequence analysis programs for the VAX.一套适用于VAX的综合序列分析程序。
Nucleic Acids Res. 1984 Jan 11;12(1 Pt 1):387-95. doi: 10.1093/nar/12.1part1.387.
2
Antibodies to plasminogen activator inhibit human tumor metastasis.纤溶酶原激活物抗体可抑制人类肿瘤转移。
Cell. 1983 Dec;35(3 Pt 2):611-9. doi: 10.1016/0092-8674(83)90093-4.
3
Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus.纤溶酶原激活剂以无活性的酶原形式从被肉瘤病毒转化的小鼠细胞中释放出来。
Eur J Biochem. 1982 May 17;124(2):409-14. doi: 10.1111/j.1432-1033.1982.tb06608.x.
4
Purification and characterization of a plasminogen activator from mouse cells transformed by an oncogenic virus.从致癌病毒转化的小鼠细胞中纯化和鉴定纤溶酶原激活剂。
Biochim Biophys Acta. 1980 Jun 13;613(2):542-55. doi: 10.1016/0005-2744(80)90110-2.
5
A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.人纤溶酶原激活剂尿激酶55,000道尔顿形式的细胞结合位点。
J Cell Biol. 1985 Jan;100(1):86-92. doi: 10.1083/jcb.100.1.86.
6
Inhibition of tumor-cell-mediated extracellular matrix destruction by a fibroblast proteinase inhibitor, protease nexin I.成纤维细胞蛋白酶抑制剂——蛋白酶nexin I对肿瘤细胞介导的细胞外基质破坏的抑制作用。
Proc Natl Acad Sci U S A. 1986 Feb;83(4):996-1000. doi: 10.1073/pnas.83.4.996.
7
Aspartic acid-484 of nascent placental alkaline phosphatase condenses with a phosphatidylinositol glycan to become the carboxyl terminus of the mature enzyme.新生胎盘碱性磷酸酶的天冬氨酸-484与磷脂酰肌醇聚糖缩合，成为成熟酶的羧基末端。
Proc Natl Acad Sci U S A. 1988 Mar;85(5):1398-402. doi: 10.1073/pnas.85.5.1398.
8
N-terminal and cDNA characterization of murine lymphocyte antigen Ly-6C.2.小鼠淋巴细胞抗原Ly-6C.2的N端及cDNA特征分析
J Immunol. 1988 Jan 1;140(1):305-10.
9
Alternative splicing: a ubiquitous mechanism for the generation of multiple protein isoforms from single genes.可变剪接：一种从单个基因产生多种蛋白质异构体的普遍机制。
Annu Rev Biochem. 1987;56:467-95. doi: 10.1146/annurev.bi.56.070187.002343.
10
COOH-terminal requirements for the correct processing of a phosphatidylinositol-glycan anchored membrane protein.磷脂酰肌醇聚糖锚定膜蛋白正确加工的羧基末端要求。
J Biol Chem. 1988 Jul 15;263(20):10016-21.
Zotero 插件